Search results
Results from the WOW.Com Content Network
Cannabinoids can be administered by smoking, vaporizing, oral ingestion, transdermal patch, intravenous injection, sublingual absorption, or rectal suppository. Once in the body, most cannabinoids are metabolized in the liver, especially by cytochrome P450 mixed-function oxidases, mainly CYP 2C9. [48]
Cannabinoid receptors are activated by cannabinoids, generated naturally inside the body (endocannabinoids) or introduced into the body as cannabis or a related synthetic compound. [10] Similar responses are produced when introduced in alternative methods, only in a more concentrated form than what is naturally occurring.
3D model of 2-Arachidonoylglycerol, an endocannaboid. The endocannabinoid system (ECS) is a biological system composed of endocannabinoids, which are neurotransmitters that bind to cannabinoid receptors, and cannabinoid receptor proteins that are expressed throughout the central nervous system (including the brain) and peripheral nervous system.
Cannabinoid receptor 1 (CB1), is a G protein-coupled cannabinoid receptor that in humans is encoded by the CNR1 gene. [5] And discovered, by determination and characterization in 1988, [6] and cloned in 1990 for the first time. [7] [8] [9] The human CB1 receptor is expressed in the peripheral nervous system and central nervous system. [5]
The cannabinoid receptor 2 (CB2), is a G protein-coupled receptor from the cannabinoid receptor family that in humans is encoded by the CNR2 gene. [5] [6] It is closely related to the cannabinoid receptor 1 (CB1), which is largely responsible for the efficacy of endocannabinoid-mediated presynaptic-inhibition, the psychoactive properties of tetrahydrocannabinol (THC), the active agent in ...
[19] [20] [26] As the legal landscape and understanding about the differences in medical cannabinoids unfolds, experts are working to distinguish "medical cannabis" (with varying degrees of psychotropic effects and deficits in executive function) from "medical CBD therapies", which would commonly present as having a reduced or non-psychoactive ...
In 2006, it was discovered that H4CBD has a binding affinity of 145 nM at the CB1 receptor and potential anti-inflammatory effects independent of its cannabinoid receptor action. [2] In contrast, CBD has been found to bind to the CB1 receptor as an inverse agonist/antagonist with a K i ranging from 3.3 to 4.8 mM.
THCA synthase is expressed in the glandular trichomes of Cannabis sativa. THCA synthase may contribute to the self-defense of Cannabis plants by producing THCA and hydrogen peroxide, which are both cytotoxic. Because these products are toxic to the plant, THCA synthase is secreted into the trichome storage cavity. [7]